Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.
Expert Rev Vaccines
; 12(6): 617-29, 2013 Jun.
Article
en En
| MEDLINE
| ID: mdl-23750792
ABSTRACT
Concurrent with the US FDA's approval of the first therapeutic cancer vaccine, and supported by mounting clinical evidence indicating that targeting carcinoembryonic antigen (CEA) can safely overcome pre-existing tolerance, a multitude of novel CEA cancer vaccines are now in various stages of development. Since cancer-driven immune suppression often limits the efficacy of vaccines, numerous strategies are being examined in both preclinical and clinical settings to overcome immunosuppressive elements, including the combined use of vaccines with certain chemotherapies, immune checkpoint inhibitors, small-molecule targeted therapies and radiation. This review discusses the current state and future direction of therapeutic cancer vaccines targeting CEA, based on advances achieved over the last 5 years.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Antígeno Carcinoembrionario
/
Vacunas contra el Cáncer
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Expert Rev Vaccines
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos